MLH1 and neoplasm: First, the efficacy, particularly the specificity of MMR IHC and MSI testing for LS pre-screening of tumor samples, may be improved by excluding patients with dMMR/MSI-H caused by methylation of the MLH1 promoter or double somatic MMR variants13,38.